2021 Revenues ($USD) : $5,880,371,449
2021 Revenues (foreign currencies) : JP¥645,942,000,000
2021 R&D spend : $1,368,344,865.26
2021 Number of Employees : 11,237
Fiscal Year End : 3/31/2021
Leader : CEO Haruo Naito

A result of the merger of two labs in 1944, Esai focuses on developing drugs for oncology and neurology indications. The company has a global network of R&D facilities with 14 drug discovery centers globally, manufacturing sites and marketing subsidiaries. Key products include the anti-cancer medication Lenvima (lenvatinib), the chemotherapy Halaven (eribulin mesylate), the anticonvulsant Banzel (rufinamide), the anti-epileptic medicine Fycompa (perampanel) and the insomnia treatment Dayvigo (lemborexant). —BB